Pathkey.AI Ltd (PKY.AX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 1 | 1 | 1 | 0 | 0 | 0 | - | - |
| Operating profit | AUD m | -2 | - | ||||||
| Net profit | AUD m | -1 | -2 | -2 | -3 | -3 | -1 | - | - |
| EPS reported | AUD | -0.01 | - | ||||||
| Operating cashflow per share | AUD | -0.01 | - | ||||||
| Capex per share | AUD | 0.00 | - | ||||||
| FCF per share | AUD | -0.01 | - | ||||||
| Free cash flow | AUD m | -1 | - | ||||||
| Net debt | AUD m | -0 | - | ||||||
| Book value equity | AUD m | -0 | - | ||||||
| Book value per share | AUD | -0.00 | - | ||||||
| Number of shares | m | 200.13 | - | ||||||
| DPS (TTM paid) | AUD | 0.00 | - |
Financial summary
Financials in AUDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -21.63 | - | ||||||
| P/S LTM | x | 208.90 | - | ||||||
| P/FCF LTM | x | -4.50 | - | ||||||
| EV/EBITDA LTM | x | -3.68 | - | ||||||
| EV/Sales LTM | x | 219.85 | - | ||||||
| Earnings Yield LTM | % | -24.94% | - | ||||||
| FCF Yield | % | -22.21% | - | ||||||
| Quality | |||||||||
| ROE | % | +539.47% | - | ||||||
| ROIC | % | -9.67% | - | ||||||
| Operating margin | % | -60.01% | - | ||||||
| Gross margin | % | -28.03% | - | ||||||
| FCF/Sales | % | -4639.20% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -93.01% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -3.13 | - | ||||||
| Net Debt/EBITDA | x | -0.18 | - | ||||||
| EBIT/Net interest | x | -22.29 | - | ||||||
| Net debt/market cap | % | +7.09% | - | ||||||
| Net debt/Equity | x | 0.09 | - | ||||||
| Gross debt/equity | x | -1.53 | - | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free